Debt to Equity Ratio Chart

View Debt to Equity Ratio for BIIB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 0.4433
March 31, 2026 0.3518
December 31, 2025 0.3647
September 30, 2025 0.3619
June 30, 2025 0.374
March 31, 2025 0.39
December 31, 2024 0.4018
September 30, 2024 0.4066
June 30, 2024 0.4191
March 31, 2024 0.4566
December 31, 2023 0.5019
September 30, 2023 0.5327
June 30, 2023 0.4555
March 31, 2023 0.4791
December 31, 2022 0.5009
September 30, 2022 0.5193
June 30, 2022 0.636
March 31, 2022 0.6749
December 31, 2021 0.706
September 30, 2021 0.7305
June 30, 2021 0.7099
March 31, 2021 0.7159
December 31, 2020 0.7394
September 30, 2020 0.7282
June 30, 2020 0.6931
Date Value
March 31, 2020 0.5073
December 31, 2019 0.4827
September 30, 2019 0.4597
June 30, 2019 0.4975
March 31, 2019 0.4665
December 31, 2018 0.4553
September 30, 2018 0.4308
June 30, 2018 0.4835
March 31, 2018 0.4221
December 31, 2017 0.4708
September 30, 2017 0.5063
June 30, 2017 0.5623
March 31, 2017 0.5675
December 31, 2016 0.5368
September 30, 2016 0.5393
June 30, 2016 0.5738
March 31, 2016 0.6334
December 31, 2015 0.6963
September 30, 2015 0.618
June 30, 2015 0.0461
March 31, 2015 0.0501
December 31, 2014 0.0541
September 30, 2014 0.0563
June 30, 2014 0.0617
March 31, 2014 0.0651

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
Ionis Pharmaceuticals, Inc. 4.978
AbbVie, Inc. -11.93
Gilead Sciences, Inc. 2.219
Vertex Pharmaceuticals, Inc. 0.0977
Amgen, Inc. 4.903